PT  - JOURNAL ARTICLE
AU  - Singh, Karandeep
AU  - Valley, Thomas S.
AU  - Tang, Shengpu
AU  - Li, Benjamin Y.
AU  - Kamran, Fahad
AU  - Sjoding, Michael W.
AU  - Wiens, Jenna
AU  - Otles, Erkin
AU  - Donnelly, John P.
AU  - Wei, Melissa Y.
AU  - McBride, Jonathon P.
AU  - Cao, Jie
AU  - Penoza, Carleen
AU  - Ayanian, John Z.
AU  - Nallamothu, Brahmajee K.
TI  - Evaluating a Widely Implemented Proprietary Deterioration Index Model Among Hospitalized COVID-19 Patients
AID  - 10.1101/2020.04.24.20079012
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.24.20079012
4099  - http://medrxiv.org/content/early/2020/06/20/2020.04.24.20079012.short
4100  - http://medrxiv.org/content/early/2020/06/20/2020.04.24.20079012.full
AB  - Introduction The Epic Deterioration Index (EDI) is a proprietary prediction model implemented in over 100 U.S. hospitals that was widely used to support medical decision-making during the COVID-19 pandemic. The EDI has not been independently evaluated, and other proprietary models have been shown to be biased against vulnerable populations.Methods We studied adult patients admitted with COVID-19 to non-ICU care at a large academic medical center from March 9 through May 20, 2020. We used the EDI, calculated at 15-minute intervals, to predict a composite outcome of ICU-level care, mechanical ventilation, or in-hospital death. In a subset of patients hospitalized for at least 48 hours, we also evaluated the ability of the EDI to identify patients at low risk of experiencing this composite outcome during their remaining hospitalization.Results Among 392 COVID-19 hospitalizations meeting inclusion criteria, 103 (26%) met the composite outcome. Median age of the cohort was 64 (IQR 53-75) with 168 (43%) African Americans and 169 (43%) women. Area under the receiver-operating-characteristic curve (AUC) of the EDI was 0.79 (95% CI 0.74-0.84). EDI predictions did not differ by race or sex. When exploring clinically-relevant thresholds of the EDI, we found patients who met or exceeded an EDI of 68.8 made up 14% of the study cohort and had a 74% probability of experiencing the composite outcome during their hospitalization with a median lead time of 24 hours from when this threshold was first exceeded. Among the 286 patients hospitalized for at least 48 hours who had not experienced the composite outcome, 14 (13%) never exceeded an EDI of 37.9, with a negative predictive value of 90% and a sensitivity above this threshold of 91%.Conclusion We found the EDI identifies small subsets of high- and low-risk COVID-19 patients with fair discrimination. We did not find evidence of bias by race or sex. These findings highlight the importance of independent evaluation of proprietary models before widespread operational use among COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTSV was supported by grant K23 HL140165 from the National Heart, Lung, and Blood Institute. JPD was supported by grant K12-HL138039 from the National Heart, Lung, and Blood Institute. MYW was supported by grant K23 AG056638 from the National Institute on Aging. MWS, JW, and BKN were supported by grant R01 LM013325-01 from the National Library of Medicine and by the Michigan Institute for Data Science. MWS was supported by grant K01 HL136687 from the National Heart, Lung, and Blood Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the University of Michigan Medical School.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data include protected health information from the University of Michigan and are not available for download. The code is available at: https://github.com/ml4lhs/edi_validationhttps://github.com/ml4lhs/edi_validation